Contains Nonbinding Recommendations

Guidance on Mirtazapine

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Mirtazapine

Form/Route: Orally Disintegrating Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 15 mg
   Subjects: Normal healthy males and females, general population
   Additional Comments: Due to safety concerns, studies on the lower strength are recommended.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 15 mg
   Subjects: Normal healthy males and females, general population
   Additional comments: Please see above comment.

Analytes to measure: Mirtazapine in plasma

Bioequivalence based on (90% CI): Mirtazapine

Waiver request of in-vivo testing: 30-mg and 45-mg based on (i) acceptable bioequivalence studies on the 15 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Finalized May 2008